The Rabbit Monoclonal anti-IL12B antibody (Clone 31I13) (ABIN7881269) specifically detects IL12B in WB, ICC, FACS and IF.
The antibody is reactive with Human samples.
Optimal dilution of the IL12B antibody should be determined by the researcher.
Restrictions
For Research Use only
Format
Liquid
Buffer
Rabbit IgG in phosphate buffered saline, pH 7.4, 150 mM NaCl, 0.02 % sodium azide and 50 % glycerol, 0.4-0.5 mg/mL BSA
Preservative
Sodium azide
Precaution of Use
This product contains Sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.
Storage
-20 °C
Storage Comment
Store the IL12B antibody at -20oC.
Target
IL12B
(Interleukin 12 beta (IL12B))
Alternative Name
IL12B
Background
IL12B antibody detects interleukin 12 subunit beta, encoded by the IL12B gene. IL12B forms part of two heterodimeric cytokines, interleukin 12 and interleukin 23. In interleukin 12, IL12B pairs with the IL12A subunit to promote Th1 differentiation and interferon gamma production, supporting cellular immunity against intracellular pathogens. In interleukin 23, IL12B pairs with IL23A to stimulate Th17 responses and production of IL17, driving neutrophilic inflammation. Through these dual roles, IL12B is central to both protective immunity and inflammatory disease.
IL12B antibody is widely applied in immunology, inflammation, and translational medicine. By detecting IL12B, researchers can examine how immune signaling shapes host defense and pathology. Elevated IL12B expression contributes to autoimmune diseases such as psoriasis, Crohn disease, and multiple sclerosis. Conversely, defective IL12B leads to increased susceptibility to infection due to impaired Th1 responses.
ELISA quantifies IL12B in serum or culture supernatants. Western blot assays detect IL12B protein bands in activated immune cell lysates. Immunohistochemistry maps expression in lymphoid tissues, while immunofluorescence highlights secretion patterns in dendritic cells and macrophages. These diverse applications make IL12B antibody a versatile tool for immune research.
IL12B has therapeutic relevance as a target of monoclonal antibodies that block interleukin 12 and interleukin 23 signaling. Agents such as ustekinumab neutralize IL12B and provide clinical benefit in psoriasis and inflammatory bowel disease. By applying IL12B antibody, scientists can evaluate pathway activity and therapeutic responses in autoimmune and inflammatory disorders.
IL12B antibody from NSJ Bioreagents delivers strong specificity for analyzing cytokine biology. Its performance across multiple methods supports research into immune signaling and translational medicine.